PEDIATRICS Vol. 82 No. 6 December 1988, pp. 863-869
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stapleton, F. B.
Right arrow Articles by Murphy, S. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stapleton, F. B.
Right arrow Articles by Murphy, S. B.

Acute Renal Failure at Onset of Therapy for Advanced Stage Burkitt Lymphoma and B Cell Acute Lymphoblastic Lymphoma

F. Bruder Stapleton MD1, Douglas R. Strother MD1, Shane Roy III MD1, Robert J. Wyatt MD1, Charles P. McKay MD1, and Sharon B. Murphy MD1

1 From the Sections of Pediatric Nephrology and Pediatric Hematology/Oncology, St Jude Children's Research Hospital; Department of Pediatrics, University of Tennessee; and LeBonheur Children's Medical Center, Memphis

Aggressive therapeutic maneuvers to reduce the risk for acute renal failure are routine in the management f children receiving therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic leukemia. The case histories of 40 children entered into a prospective treatment protocol for high-risk disease revealed that ten of 40 patients (25%) had acute renal failure, two at the time of hospital admission and eight in whom renal insufficiency developed 12 to 132 hours following initiation of cytotoxic chemotherapy. Admission values for serum lactic dehydrogenase and serum uric acid were not statistically different between patients with and without subsequent renal failure. Urine output in the 12 hours prior to antineoplastic therapy was 2.9 ± 0.8 mL/kg/h in the eight children in whom renal failure developed and 5.3 ± 0.4 mL/kg/h in the patients who did not (P < .01). The urinary flow rate in the 24 hours following initiation of chemotherapy was significantly lower in children in whom renal impairment developed (1.0 ± 0.2 mL/kg/h, mean ± SE) compared with those who did not (3.7 ± 0.3 mL/kg/h, P < .001). Renal failure could not be attributed to hyperuricemia or hyperphosphatemia in the majority of patients with renal failure. One to four hemodialysis treatments (2.5 ± 0.3) were required for the ten patients. Serum creatinine concentrations returned to normal in the nine survivors. Response to initial antineoplastic therapy was not affected by the presence of renal failure. Renal failure continues to be a major clinical problem in children with Burkitt lymphoma and B cell lymphoblastic leukemia. Oliguria during initial fluid management should alert physicians to patients who may require dialysis during induction chemotherapy.

Key Words: renal failure • Burkitt lymphoma • B cell acute lymphoblastic leukemia • dialysis • tumor lysis • uric acid

Submitted on August 11, 1987
Accepted on October 12, 1987




This article has been cited by other articles:


Home page
 haematolHome page
P. Montesinos, I. Lorenzo, G. Martin, J. Sanz, M. L. Perez-Sirvent, D. Martinez, G. Orti, L. Algarra, J. Martinez, F. Moscardo, et al.
Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model
Haematologica, January 1, 2008; 93(1): 67 - 74.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
T. Atamer, B. Artim-Esen, S. Yavuz, and T. Ecder
Massive post-obstructive diuresis in a patient with Burkitt's lymphoma
Nephrol. Dial. Transplant., September 1, 2005; 20(9): 1991 - 1993.
[Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
B. Bickert and A. Reilly
Pediatric Tumor Lysis Syndrome
Journal of Pharmacy Practice, December 1, 2004; 17(6): 447 - 454.
[Abstract] [PDF]

Home page
 BloodHome page
S. C. Goldman, J. S. Holcenberg, J. Z. Finklestein, R. Hutchinson, S. Kreissman, F. L. Johnson, C. Tou, E. Harvey, E. Morris, and M. S. Cairo
A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis
Blood, May 15, 2001; 97(10): 2998 - 3003.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C.-H. Pui, H. H. Mahmoud, J. M. Wiley, G. M. Woods, G. Leverger, B. Camitta, C. Hastings, S. M. Blaney, M. V. Relling, and G. H. Reaman
Recombinant Urate Oxidase for the Prophylaxis or Treatment of Hyperuricemia in Patients With Leukemia or Lymphoma
J. Clin. Oncol., February 1, 2001; 19(3): 697 - 704.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
L. D. NICOLA, V. BELLIZZI, R. MINUTOLO, M. CIOFFI, P. GIANNATTASIO, V. TERRACCIANO, C. IODICE, F. UCCELLO, B. MEMOLI, B. R. D. IORIO, et al.
Effect of Dialysate Sodium Concentration on Interdialytic Increase of Potassium
J. Am. Soc. Nephrol., December 1, 2000; 11(12): 2337 - 2343.
[Abstract] [Full Text]

Home page
 JCOHome page
J. C. Byrd, J. K. Waselenko, T. J. Maneatis, T. Murphy, F. T. Ward, B. P. Monahan, M. A. Sipe, S. Donegan, and C. A. White
Rituximab Therapy in Hematologic Malignancy Patients With Circulating Blood Tumor Cells: Association With Increased Infusion-Related Side Effects and Rapid Blood Tumor Clearance
J. Clin. Oncol., March 1, 1999; 17(3): 791 - 791.
[Abstract] [Full Text] [PDF]